5 nurses on same floor of Boston-area hospital develop brain tumors
Five nurses who worked on the same floor of a Boston-area hospital have all developed brain tumors.
In total, 11 members of the fifth-floor maternity unit at Mass General's Newton-Wellesley Hospital have reported suffering from health issues, including the nurses diagnosed with the benign tumors. Two of those have the most common, benign type — meningioma — according to the hospital, which is located about 10 miles west of Boston.
The hospital did not provide specifics regarding the conditions of the other six staffers, saying only that they suffered from unspecified health issues, NBC reported.
In response to the cluster, the Newton hospital launched an investigation 'in collaboration with the Department of Occupational Health and Safety,' but did not uncover any 'environmental risks which could be linked to the development of a brain tumor,' Jonathan Sonis, the hospital's associate chief medical officer, and Sandy Muse, chief nursing officer, said in a statement to the network.
The probe ruled out the water supply, disposable masks, nearby X-rays and chemotherapy treatment on the floor below as potential triggers, the hospital added.
'Every staff member who came forward was given the opportunity to be interviewed by the Occupational Health and Safety team to evaluate each diagnosis in the context of their individual medical history and risk factors,' the statement continued. 'As always, the health and well-being of our staff, clinicians, and patients is our absolute top priority.'
But the Massachusetts Nurses Association has taken issue with the conclusion, claiming the hospital's review of the environmental factors was 'not comprehensive,' NBC Boston reported. The union added that it has begun looking into the matter on its own.
'The hospital cannot make this issue go away by attempting to provide a predetermined conclusion,' MNA said in a statement.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
2 hours ago
- Business Wire
Avanzanite Announces Pan-European Partnership with Agios to Launch PYRUKYND ® in Rare Blood Disorders
AMSTERDAM--(BUSINESS WIRE)--Avanzanite Bioscience B.V. ('Avanzanite'), a fast-growing commercial-stage specialty pharmaceutical company dedicated to bringing rare disease medicines to patients across Europe, announced today an exclusive agreement with Agios Pharmaceuticals Inc. (Nasdaq: AGIO), a Boston-based biotech company focused on the development and commercialization of rare disease medicines. Under the agreement, Avanzanite will commercialize and distribute PYRUKYND® (mitapivat) across the European Economic Area, the UK and Switzerland. 'This partnership marks a major milestone in our mission to transform how rare disease therapies reach patients in Europe' Share 'This partnership marks a major milestone in our mission to transform how rare disease therapies reach patients in Europe,' said Adam Plich, Founder and CEO of Avanzanite. 'We provide biotech partners with a capital-efficient path to sustainable patient access – without the burden of building a costly local infrastructure. We look forward to working with Agios to help bring PYRUKYND® to patients across Europe, further advancing our efforts to set a new benchmark for biotech commercial and distribution partnerships in the region. This is just the beginning.' PYRUKYND®, a first-in-class, oral, pyruvate kinase (PK) activator, is approved by the European Commission and the UK's Medicines and Healthcare products Regulatory Agency for the treatment of adult patients with PK deficiency. PK deficiency is an ultra-rare, inherited condition that causes premature red blood cell breakdown, leading to chronic anemia, serious complications, and reduced quality of life. Until recently, there were no approved treatments. Agios also has a robust mid- and late-stage pipeline, with clinical programs focused on other rare diseases, including thalassemia and sickle cell disease. The partnership also includes potential future indications. Avanzanite is rapidly scaling its operations, having tripled its revenue in Q1 2025 year-over-year, with two rare disease medicines already on the market. Over the next 12 months, the company will expand into 32 European countries, including new territories of Italy, France, the UK, Romania, and Spain. 'Avanzanite goes truly pan-European,' concluded Plich. 'And as we expand across the continent, our promise stays the same – making sure no patient is left behind.' About Avanzanite Avanzanite is redefining launches of rare disease medicines across Europe. Founded in 2022 and based in Amsterdam, the company partners with biotech innovators to unlock the full commercial value of orphan medicines continent-wide. With our deep expertise in market access, we navigate Europe's complex landscape like master chess players – ensuring no patient is left behind. Learn more at
San Francisco Chronicle
2 hours ago
- San Francisco Chronicle
The Latest: Trump's travel ban takes effect as tensions escalate over immigration enforcement
President Donald Trump's new ban on travel to the U.S. by citizens from 12 mainly African and Middle Eastern countries took effect Monday amid rising tension over the president's escalating campaign of immigration enforcement. Meanwhile, scores of scientists at the National Institutes of Health sent their Trump-appointed leader a letter titled the Bethesda Declaration, a frontal challenge to policies they say undermine the NIH mission, waste public resources and harm people's health. In the 'Bethesda Declaration,' NIH scientists step forward en masse to denounce their agency's direction Scores of National Institutes of Health scientists have gone public to assail deep program cuts and upheaval at their agency under the Trump administration. On Monday, more than 90 current employees sent their leader a letter entitled the Bethesda Declaration. It's a frontal challenge to policies it says 'undermine the NIH mission, waste our public resources, and harm the health of Americans and people across the globe.' By signing their names, the NIH employees gave up the veil of anonymity common in Washington — and put their jobs at risk. Their declaration was endorsed anonymously by 250 other NIH researchers and staff. Altogether, employees from all 27 NIH institutes and centers registered their dismay with the agency's direction. Trump says Elon Musk could face 'serious consequences' if he backs Democratic candidates Trump is not backing off his battle with Elon Musk, saying Saturday that he has no desire to repair their relationship and warning that his former ally and campaign benefactor could face 'serious consequences' if he tries to help Democrats in upcoming elections. Trump told NBC's Kristen Welker in a phone interview that he has no plans to make up with Musk. Asked specifically if he thought his relationship with the mega-billionaire CEO of Tesla and SpaceX is over, Trump responded, 'I would assume so, yeah.' 'I'm too busy doing other things,' Trump said. The president also issued a warning amid chatter that Musk could back Democratic lawmakers and candidates in the 2026 midterm elections. 'If he does, he'll have to pay the consequences for that,' Trump told NBC, though he declined to share what those consequences would be. Musk's businesses have many lucrative federal contracts. Mike Johnson downplays Musk's influence and says Republicans will pass Trump's tax and budget bill Johnson took clear sides Sunday in Trump's breakup with mega-billionaire Elon Musk, saying Musk's criticism of the GOP's massive tax and budget policy bill will not derail the measure, and he downplayed Musk's influence over the GOP-controlled Congress. 'I didn't go out to craft a piece of legislation to please the richest man in the world,' Johnson said on ABC's 'This Week.' Johnson said he has exchanged text messages with Musk since he came out against the GOP bill. Musk called it an 'abomination' that would add to U.S. debts and threaten economic stability. He urged voters to flood Capitol Hill with calls to vote against the measure, which is pending in the Senate after clearing the House. His criticism sparked an angry social media back-and-forth with Trump, who told reporters over the weekend that he has no desire to repair his relationship with Musk. The speaker was dismissive of Musk's threats to finance opponents — even Democrats — of Republican members who back Trump's bill. Trump's new travel ban takes effect as tensions escalate over immigration enforcement Trump's new ban on travel to the U.S. by citizens from 12 mainly African and Middle Eastern countries took effect Monday amid rising tension over the president's escalating campaign of immigration enforcement. The new proclamation, which Trump signed last week, applies to citizens of Afghanistan, Myanmar, Chad, the Republic of Congo, Equatorial Guinea, Eritrea, Haiti, Iran, Libya, Somalia, Sudan and Yemen. It also imposes heightened restrictions on people from Burundi, Cuba, Laos, Sierra Leone, Togo, Turkmenistan and Venezuela who are outside the U.S. and don't hold a valid visa. The new ban does not revoke visas previously issued to people from countries on the list, according to guidance issued Friday to all U.S. diplomatic missions. However, unless an applicant meets narrow criteria for an exemption to the ban, his or her application will be rejected starting Monday. Travelers with previously issued visas should still be able to enter the U.S. even after the ban takes effect.
Yahoo
11 hours ago
- Yahoo
Boston Medflight hosts heartwarming annual event that reunites patients with their caretakers
Boston MedFlight staff were reunited with the patients they served in their most critical and vulnerable moments. Boston MedFlight celebrates its 40th year of service, and with this annual event, it helps bring heartwarming moments for families and patients to reunite with the aviation members who cared for them in their most critical moments. Christine Muszalsk, a registered nurse who started the event back in 2001, says it's important to pause and acknowledge this work. 'A day like this is a reminder of how fragile life is and how important the work is that we do to help our patients.' Boston MedFlight is a non-profit organization that provides millions of dollars every year in free and unreimbursed care to patients with little or no medical insurance. This is a developing story. Check back for updates as more information becomes available. Download the FREE Boston 25 News app for breaking news alerts. Follow Boston 25 News on Facebook and Twitter. | Watch Boston 25 News NOW
